Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Journal article
Authors / Editors
No matching items found.
Research Areas
No matching items found.
Publication Details
Author list: Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, Sanchez J, Essex M, Makhema J, Kiarie J, Farquhar C, Corey L
Publisher: University of Chicago Press / Oxford University Press (OUP): Policy B - Oxford Open Option C
Publication year: 2011
Journal: The Journal of Infectious Diseases (0022-1899)
Journal acronym: J Infect Dis
Volume number: 203
Issue number: 1
Start page: 117
End page: 21
Number of pages: -95
ISSN: 0022-1899
eISSN: 1537-6613
Languages: English-Great Britain (EN-GB)
Abstract
Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.
Keywords
No matching items found.
Documents
No matching items found.
